Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women;Vergleich der wirksamkeit und sicherheit von minoxidil und alfatradiol bei der topischen behandlung der androgenetischen alopezie der frau

JDDG - Journal of the German Society of Dermatology

Volumn 5, Issue 5, 2007, Pages 391-395

  Blume Peytavi, Ulrike ^a   Kunte, Christian ^b   Krisp, Andreas ^c   Bartels, Natalie Garcia ^a   Ellwanger, Ulf ^d   Hoffmann, Rolf ^e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c Praxis für Dermatologie und Allergologie   (Germany)

^d DatInf GmbH   (Germany)

^e Praxen für Dermatologie und Phlebologie   (Germany)

Author keywords

Alfatradiol; Androgenetic alopecia in women; Cumulative hair thickness; Efficacy; Hair density; Minoxidil; TrichoScan

Indexed keywords

17ALPHA ESTRADIOL; ELL CRANEL; MINOXIDIL; PANTOSTIN; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HAIR GROWTH; HUMAN; MAJOR CLINICAL STUDY; MALE TYPE ALOPECIA; MULTICENTER STUDY; PHASE 4 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; THICKNESS; TOPICAL TREATMENT; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 34247473967     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2007.06295.x     Document Type: Article

References (16)

1. Blume-Peytavi U. Anlagebedingter Haarausfall und aktuelle Therapiekonzepte (Androgenetic hair loss and modern therapeutic concepts). Akt Dermatol 2002 28 : S19 23.
2. Van Neste DJJ, Rushton DH. Hair problems in women. Clin Dermatol 1997 15 : 113 125.
3. Birch MP, Messenger JF, Messenger AG. Hair densitiy, hair diameter and the prevalence of female pattern hair loss. Br J Dermatol 2001 144 : 297 304.
4. Wolff H, Kunte C. Haarausfall und Alopezien bei Frauen (Hair loss and alopecia in women). Gynäkologe 2003 36 (7 605 616.
5. Price VH, Menefee E, Sanchez M, Ruane P, Kaufmann KD. Changes in hair weight and hair count in men with androgenetic alopecia, after application of 5% and 2% topical minoxidil, placebo, or no treatment. J Am Acad Dermatol 1999 41 (5 717 721.
6. Sinclair RD, Dawber RPR. Androgenetic alopecia in men and women. Clin Dermatol 2001 19 : 167 178.
7. Ramos-e Silva M. Male pattern hair loss - Prevention rather than regrowth. Int J Dermatol 2000 39 : 728 731.
8. Hoffmann R. TrichoScan - Ein neues Werkzeug für die digitale Haarzählung. Hautarzt 2002 53 : 798 804.
9. Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol 1977 97 : 247 254.
10. Hoffmann R. TrichoScan - What is new? Dermatology 2005 211 (1 54 62.
11. Wozel G, Narayanan S, Jäckel A, Lutz GA. Alfatradiol (0,025%) - Eine wirksame und sichere Therapieoption zur Behandlung der androgenetischen Alopezie bei Frauen und Männern (Alfatradiol (0,025%) - An effective and safe therapy for the treatment of androgenetic alopecia in women and man). Aktuell Dermatol 2005 31 (12 553 560.
12. Orfanos CE, Vogels L. Lokaltherapie der Alopecia androgenetica mit 17 α- Östradiol. Dermatoligica 1980 161 : 124 132.
13. DeVillez RL, Jacobs JP, Szpunar CA, Warner ML. Androgenetic alopecia in the female - Treatment with 2% topical minoxidil solution. Arch Dermatol 1994 130 : 303 307.
14. Jacobs JP, Szpunar CA, Warner ML. Use of topical minoxidil therapy for androgenetic alopecia in women. Int J Dermatol 1993 32 : 758 762.
15. Lucky AW, Piacquadio DJ, Ditre CM, Dunlap F, Kantor I, Pandya AG, Savin RC, Tharp MD. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol 2004 50 (4 541 553.
16. Vexiau P Chaspoux C, Boudou P, Fiet J, Jouanique C, Hardy N, Reygagne P. Effects of minoxidil 2% vs cyproterone acetate treatment on female androgenetic alopecia - A controlled, 12-month randomized trial. Br J Dermatol 2002 146 (6 992 999.